877674-94-7

Basic information

• Product Name: Benzoic acid, 4-(4-thiazolyl)-, methyl ester
• CAS NO: 877674-94-7
• Molecular Formula: C11H9NO2S
• Molecular Weight: 219.264
• Mol File: 877674-94-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(4-thiazolyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(4-thiazolyl)-, methyl ester(877674-94-7)
• EPA Substance Registry System: Benzoic acid, 4-(4-thiazolyl)-, methyl ester(877674-94-7)

Safety Data

• Hazardous Substances Data: 877674-94-7(Hazardous Substances Data)

Upstream product

• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 34259-99-9 4-bromo-1,3-thiazole 

Downstream Products

• 877674-95-8 4-thiazol-4-yl-benzoic acid, lithium salt 

Relevant articles and documents

Identification of Piperidine-3-carboxamide Derivatives Inducing Senescence-like Phenotype with Antimelanoma Activities

This study evaluated the potential use of senescence-inducing small molecules in the treatment of melanoma. We screened commercially available small-molecule libraries with high-throughput screening and high-content screening image-based technology. Our findings showed an initial hit with the embedded N-arylpiperidine-3-carboxamide scaffold-induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells. A focused library containing diversely modified analogues were constructed and examined to evaluate the structure-activity relationship of N-arylpiperidine-3-carboxamide derivatives starting from hit 1. This work identified a novel compound with remarkable antiproliferative activity in vitro and demonstrated the key structural moieties within.

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.